Skip to content
Men Under Microscope – Lifestyle
Home
Sample Page
Author:
HitGen Inc.
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
July 14, 2026
ESG | HitGen Releases 2025 Sustainability Report
April 29, 2026